Published in Curr HIV Res on July 01, 2013
Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines. Clin Vaccine Immunol (2014) 1.06
Different infectivity of HIV-1 strains is linked to number of envelope trimers required for entry. PLoS Pathog (2015) 0.92
Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain's exceptional capacity for sequence variation. Retrovirology (2014) 0.86
Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor. PLoS One (2015) 0.77
Vaccine focusing to cross-subtype HIV-1 gp120 variable loop epitopes. Vaccine (2014) 0.75
Structural Elements Recognized by Abacavir-Induced T Cells. Int J Mol Sci (2017) 0.75
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature (1985) 30.47
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature (1998) 24.69
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet (2008) 19.65
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science (2009) 17.14
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med (2005) 17.06
Atomic structure of the ectodomain from HIV-1 gp41. Nature (1997) 16.31
CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med (2004) 13.55
Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol (1999) 13.55
Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 12.98
Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science (1998) 12.81
Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature (2002) 12.49
Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature (2011) 11.07
CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature (1996) 10.27
HIV evolution: CTL escape mutation and reversion after transmission. Nat Med (2004) 10.21
Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis (2005) 10.20
Diversity considerations in HIV-1 vaccine selection. Science (2002) 9.60
HIV entry and its inhibition. Cell (1998) 9.42
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet (2008) 8.37
A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science (1998) 8.36
Structure of an unliganded simian immunodeficiency virus gp120 core. Nature (2005) 8.30
Molecular architecture of native HIV-1 gp120 trimers. Nature (2008) 8.04
Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis (2006) 7.98
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature (2011) 7.20
Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell (1988) 7.01
T-cell function and migration. Two sides of the same coin. N Engl J Med (2000) 6.47
Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med (2004) 6.46
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22
Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol (2005) 5.92
Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol (2000) 5.71
Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis (2008) 5.69
Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol (2008) 5.69
Capture of an early fusion-active conformation of HIV-1 gp41. Nat Struct Biol (1998) 5.62
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature (2012) 5.49
Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science (2004) 5.31
Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science (1986) 5.25
HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J Exp Med (2004) 5.08
HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol (2008) 5.01
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity (2013) 4.82
Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J Virol (1992) 4.72
Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J Virol (2007) 4.64
The role of antibodies in HIV vaccines. Annu Rev Immunol (2010) 4.50
The immunological synapse. Annu Rev Immunol (2001) 4.45
The structural biology of type I viral membrane fusion. Nat Rev Mol Cell Biol (2003) 4.21
The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol (2011) 4.18
ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol (2002) 4.11
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol (2011) 4.06
Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J Virol (2005) 3.93
Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol (2009) 3.85
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature (2012) 3.83
Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis (2011) 3.71
Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J Virol (1994) 3.70
Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J Virol (1997) 3.46
Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J Exp Med (2001) 3.44
Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J Immunol (1993) 3.39
The HIV Env-mediated fusion reaction. Biochim Biophys Acta (2003) 3.37
Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J Virol (1994) 3.33
Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Structure (2004) 3.31
Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. J Exp Med (2008) 3.20
Critical role for beta7 integrins in formation of the gut-associated lymphoid tissue. Nature (1996) 3.11
Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. PLoS Pathog (2012) 3.07
Evidence for a functional interaction between the V1/V2 and C4 domains of human immunodeficiency virus type 1 envelope glycoprotein gp120. J Virol (1994) 3.07
Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection. AIDS Res Hum Retroviruses (1996) 3.01
DC-SIGN-ICAM-2 interaction mediates dendritic cell trafficking. Nat Immunol (2000) 2.98
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis (2012) 2.89
Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol (2010) 2.76
Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immunol (2006) 2.72
Suppression of simian immunodeficiency virus replication in vitro by CD8+ lymphocytes. J Immunol (1988) 2.68
Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis (2012) 2.68
Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. PLoS Pathog (2010) 2.55
Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization. J Virol (1994) 2.52
Policy rebuttal. HIV vaccine trial justified. Science (2004) 2.49
Understanding the genetic diversity of HIV-1. AIDS (2000) 2.39
Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proc Natl Acad Sci U S A (2011) 2.38
The genotype of early-transmitting HIV gp120s promotes α (4) β(7)-reactivity, revealing α (4) β(7) +/CD4+ T cells as key targets in mucosal transmission. PLoS Pathog (2011) 2.32
Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J Exp Med (2013) 2.31
The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci U S A (2009) 2.30
The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J Virol (2007) 2.29
Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis (2008) 2.25
HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response. J Immunol (2005) 2.24
The role of the V3 loop of gp120 in HIV infection. AIDS (1991) 2.23
Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat Rev Immunol (2010) 2.20
Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res Hum Retroviruses (2007) 2.19
IgA blocks IgM and IgG-initiated immune lysis by separate molecular mechanisms. J Immunol (1983) 2.11
N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. J Biol Chem (2001) 2.07
Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis (2004) 2.01
Alpha4(+)beta7(hi)CD4(+) memory T cells harbor most Th-17 cells and are preferentially infected during acute SIV infection. Mucosal Immunol (2009) 1.96
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses (2012) 1.94
Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7. PLoS Pathog (2012) 1.88
HIV vaccines: new frontiers in vaccine development. Clin Infect Dis (2006) 1.82
Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes. PLoS One (2010) 1.77
The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol (2012) 1.75
Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1. J Virol (2010) 1.70
Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies. PLoS Pathog (2011) 1.70
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 12.98
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature (2012) 5.49
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity (2013) 4.82
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature (2012) 3.83
Influence of HLA-C expression level on HIV control. Science (2013) 3.27
The structure of the phage T4 DNA packaging motor suggests a mechanism dependent on electrostatic forces. Cell (2008) 3.07
Host determinants of HIV-1 control in African Americans. J Infect Dis (2010) 2.90
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis (2012) 2.89
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell (2013) 2.88
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol (2012) 2.74
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med (2011) 2.71
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A (2013) 2.69
Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis (2012) 2.68
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med (2014) 2.47
Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology (2008) 2.37
Molecular architecture of the prolate head of bacteriophage T4. Proc Natl Acad Sci U S A (2004) 2.24
Reference ranges for the clinical laboratory derived from a rural population in Kericho, Kenya. PLoS One (2008) 1.97
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses (2012) 1.94
Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One (2013) 1.94
Single phage T4 DNA packaging motors exhibit large force generation, high velocity, and dynamic variability. Proc Natl Acad Sci U S A (2007) 1.92
Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. Virology (2008) 1.89
International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine (2011) 1.88
Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci Transl Med (2014) 1.87
Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection. AIDS (2003) 1.81
The structure of the ATPase that powers DNA packaging into bacteriophage T4 procapsids. Mol Cell (2007) 1.79
A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). J Infect Dis (2010) 1.79
HIV vaccines: lessons learned and the way forward. Curr Opin HIV AIDS (2010) 1.76
The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol (2012) 1.75
CCL3L1 and HIV/AIDS susceptibility. Nat Med (2009) 1.73
Identification of CRF34_01B, a second circulating recombinant form unrelated to and more complex than CRF15_01B, among injecting drug users in northern Thailand. AIDS Res Hum Retroviruses (2007) 1.69
Performance of the OraQuick rapid antibody test for diagnosis of human immunodeficiency virus type 1 infection in patients with various levels of exposure to highly active antiretroviral therapy. J Clin Microbiol (2003) 1.66
Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS One (2013) 1.65
Vaccine protection against Zika virus from Brazil. Nature (2016) 1.65
Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E. J Infect Dis (2012) 1.65
Sequence analysis of bacteriophage T4 DNA packaging/terminase genes 16 and 17 reveals a common ATPase center in the large subunit of viral terminases. Nucleic Acids Res (2002) 1.61
Reference intervals in healthy adult Ugandan blood donors and their impact on conducting international vaccine trials. PLoS One (2008) 1.55
Needle-free skin patch vaccination method for anthrax. Infect Immun (2004) 1.54
Immunologic and virologic events in early HIV infection predict subsequent rate of progression. J Infect Dis (2010) 1.53
Large-scale human immunodeficiency virus rapid test evaluation in a low-prevalence ugandan blood bank population. J Clin Microbiol (2007) 1.47
Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. PLoS One (2010) 1.41
Oral preexposure prophylaxis for HIV--another arrow in the quiver? N Engl J Med (2010) 1.40
The functional domains of bacteriophage t4 terminase. J Biol Chem (2004) 1.37
Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect Immun (2002) 1.34
HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: acquisition of syncytium-inducing virus at seroconversion. J Acquir Immune Defic Syndr (2002) 1.33
Variable contexts and levels of hypermutation in HIV-1 proviral genomes recovered from primary peripheral blood mononuclear cells. Virology (2008) 1.32
The DNA translocating ATPase of bacteriophage T4 packaging motor. J Mol Biol (2006) 1.31
Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. Expert Rev Vaccines (2010) 1.31
Use of rapid and conventional testing technologies for human immunodeficiency virus type 1 serologic screening in a rural Kenyan reference laboratory. J Clin Microbiol (2004) 1.31
Comparative analysis of HIV-1 viral load assays on subtype quantification: Bayer Versant HIV-1 RNA 3.0 versus Roche Amplicor HIV-1 Monitor version 1.5. J Acquir Immune Defic Syndr (2002) 1.30
Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells. J Virol (2002) 1.28
F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med (2003) 1.28
Structure and function of the small terminase component of the DNA packaging machine in T4-like bacteriophages. Proc Natl Acad Sci U S A (2011) 1.28
Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees. J Virol (2013) 1.26
Adjuvants for human vaccines. Curr Opin Immunol (2012) 1.25
Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. J Virol (2012) 1.24
Use of stored serum from Uganda for development and evaluation of a human immunodeficiency virus type 1 testing algorithm involving multiple rapid immunoassays. J Clin Microbiol (2005) 1.24
Assembly of human immunodeficiency virus (HIV) antigens on bacteriophage T4: a novel in vitro approach to construct multicomponent HIV vaccines. J Virol (2006) 1.24
Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. Vaccine (2009) 1.24
A novel acute HIV infection staging system based on 4th generation immunoassay. Retrovirology (2013) 1.24
The bacteriophage DNA packaging machine. Adv Exp Med Biol (2012) 1.23
Lipid binding properties of 4E10, 2F5, and WR304 monoclonal antibodies that neutralize HIV-1. Biochim Biophys Acta (2008) 1.19
Monoclonal antibodies to phosphatidylinositol phosphate neutralize human immunodeficiency virus type 1: role of phosphate-binding subsites. J Virol (2006) 1.19
Impact of viral infection on the gene expression profiles of proliferating normal human peripheral blood mononuclear cells infected with HIV type 1 RF. AIDS Res Hum Retroviruses (2002) 1.19
Myoferlin regulates vascular endothelial growth factor receptor-2 stability and function. J Biol Chem (2007) 1.19
A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS (2002) 1.18
FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. J Clin Invest (2014) 1.18
Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation. AIDS (2002) 1.17
Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes. AIDS (2009) 1.16
An ATP hydrolysis sensor in the DNA packaging motor from bacteriophage T4 suggests an inchworm-type translocation mechanism. J Mol Biol (2007) 1.15
Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans. Vaccine (2007) 1.14
Structure of the small outer capsid protein, Soc: a clamp for stabilizing capsids of T4-like phages. J Mol Biol (2009) 1.14
Immunization with DNA through the skin. Methods (2003) 1.13
Causative factors behind poloxamer 188 (Pluronic F68, Flocor)-induced complement activation in human sera. A protective role against poloxamer-mediated complement activation by elevated serum lipoprotein levels. Biochim Biophys Acta (2004) 1.13
Multicomponent anthrax toxin display and delivery using bacteriophage T4. Vaccine (2006) 1.12
Bacteriophage T4 capsid: a unique platform for efficient surface assembly of macromolecular complexes. J Mol Biol (2006) 1.11
Gag-specific cellular immunity determines in vitro viral inhibition and in vivo virologic control following simian immunodeficiency virus challenges of vaccinated rhesus monkeys. J Virol (2012) 1.10
Structure of the three N-terminal immunoglobulin domains of the highly immunogenic outer capsid protein from a T4-like bacteriophage. J Virol (2011) 1.10
Genome packaging in viruses. Curr Opin Struct Biol (2010) 1.09
The headful packaging nuclease of bacteriophage T4. Mol Microbiol (2008) 1.08
Performance characteristics of human immunodeficiency virus type 1 (HIV-1) genotyping systems in sequence-based analysis of subtypes other than HIV-1 subtype B. J Clin Microbiol (2003) 1.08
In vitro binding of anthrax protective antigen on bacteriophage T4 capsid surface through Hoc-capsid interactions: a strategy for efficient display of large full-length proteins. Virology (2005) 1.07
Human immunodeficiency virus vaccine trials. Cold Spring Harb Perspect Med (2012) 1.05
Human erythrocytes selectively bind and enrich infectious HIV-1 virions. PLoS One (2009) 1.05
Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system. PLoS One (2013) 1.04
The small terminase, gp16, of bacteriophage T4 is a regulator of the DNA packaging motor. J Biol Chem (2009) 1.03
Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection. Annu Rev Med (2014) 1.03
Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles. J Liposome Res (2007) 1.02
Assembly of the small outer capsid protein, Soc, on bacteriophage T4: a novel system for high density display of multiple large anthrax toxins and foreign proteins on phage capsid. J Mol Biol (2007) 1.02
Modulation of dengue virus infection of dendritic cells by Aedes aegypti saliva. Viral Immunol (2004) 1.02
Salmonella pathogenicity island 2 expression negatively controlled by EIIANtr-SsrB interaction is required for Salmonella virulence. Proc Natl Acad Sci U S A (2010) 1.01